|Bid||2.0000 x 800|
|Ask||4.3300 x 1000|
|Day's Range||3.7100 - 3.9800|
|52 Week Range||2.1300 - 5.1600|
|Beta (5Y Monthly)||1.33|
|PE Ratio (TTM)||53.29|
|Earnings Date||Feb 29, 2024 - Mar 04, 2024|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.67|
Subscribe to Yahoo Finance Plus to view Fair Value for PBYI
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.